Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has been reported to elicit anti-proliferative response in various tumors. In this study, we aim to investigate the antitumor effect of celecoxib on urothelial carcinoma (UC) cells and the role endoplasmic reticulum (ER) stress plays in celecoxib-induced cytotoxicity. The cytotoxic effects were measured by MTT assay and flow cytometry. The cell cycle progression and ER stress-associated molecules were examined by Western blot and flow cytometry. Moreover, the cytotoxic effects of celecoxib combined with glucose-regulated protein (GRP) 78 knockdown (siRNA), (？)-epigallocatechin gallate (EGCG) or MG132 were assessed. We demonstrated that celecoxib markedly reduces the cell viability and causes apoptosis in human UC cells through cell cycle G1 arrest. Celecoxib possessed the ability to activate ER stress-related chaperones (IRE-1α and GRP78), caspase-4, and CCAAT/enhancer binding protein homologous protein (CHOP), which were involved in UC cell apoptosis. Down-regulation of GRP78 by siRNA, co-treatment with EGCG (a GRP78 inhibitor) or with MG132 (a proteasome inhibitor) could enhance celecoxib-induced apoptosis. We concluded that celecoxib induces cell cycle G1 arrest, ER stress, and eventually apoptosis in human UC cells. The down-regulation of ER chaperone GRP78 by siRNA, EGCG, or proteosome inhibitor potentiated the cytotoxicity of celecoxib in UC cells. These findings provide a new treatment strategy against UC.
References
[1]
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
[2]
Latini DM, Lerner SP, Wade SW, Lee DW, Quale DZ (2010) Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology 75: 334–339.
[3]
Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, et al. (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3: 1463–1470.
[4]
Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448–2458.
[5]
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068–3077.
[6]
Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431–436.
[7]
Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, et al. (2010) Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 9: 1371–1377.
[8]
Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW (2008) Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 7: 897–904.
[9]
Dovedi SJ, Kirby JA, Davies BR, Leung H, Kelly JD (2008) Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 54: 621–630.
[10]
Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, et al. (2006) Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 5: 329–336.
[11]
Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, et al. (2004) 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444–1451.
[12]
Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, et al. (2010) Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res 34: 250–253.
[13]
Huang S, Sinicrope FA (2010) Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 6: 256–269.
[14]
Jendrossek V, Handrick R, Belka C (2003) Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17: 1547–1549.
[15]
Liu X, Yue P, Zhou Z, Khuri FR, Sun SY (2004) Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96: 1769–1780.
[16]
Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, et al. (2007) Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 6: 1262–1275.
[17]
Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, et al. (2004) Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 11: 1009–1016.
[18]
Kulkarni P, Rajagopalan K, Yeater D, Getzenberg RH (2011) Protein folding and the order/disorder paradox. J Cell Biochem 112: 1949–1952.
[19]
Rutkowski DT, Kaufman RJ (2004) A trip to the ER: coping with stress. Trends Cell Biol 14: 20–28.
[20]
Wu J, Kaufman RJ (2006) From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 13: 374–384.
[21]
Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, et al. (2010) Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 9: 1399–1410.
[22]
Schonthal AH (2009) Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett 275: 163–169.
[23]
Christian BJ, Loretz LJ, Oberley TD, Reznikoff CA (1987) Characterization of human uroepithelial cells immortalized in vitro by simian virus 40. Cancer Res 47: 6066–6073.
[24]
Hour TC, Huang CY, Lin CC, Chen J, Guan JY, et al. (2004) Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide. Anticancer Drugs 15: 779–785.
[25]
Yu HJ, Tsai TC, Hsieh TS, Chiu TY (1992) Characterization of a newly established human bladder carcinoma cell line, NTUB1. J Formos Med Assoc 91: 608–613.
[26]
Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, et al. (2008) Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 68: 843–851.
[27]
Tsutsumi S, Namba T, Tanaka KI, Arai Y, Ishihara T, et al. (2006) Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 25: 1018–1029.
[28]
Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67: 3496–3499.
[29]
Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, et al. (2008) Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 6: 1268–1275.
[30]
Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, et al. (2006) (？)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 66: 9260–9269.
[31]
Egger L, Madden DT, Rheme C, Rao RV, Bredesen DE (2007) Endoplasmic reticulum stress-induced cell death mediated by the proteasome. Cell Death Differ 14: 1172–1180.
[32]
Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, et al. (2006) Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15: 471–477.
[33]
Gee JR, Burmeister CB, Havighurst TC, Kim K (2009) Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer. Anticancer Res 29: 3769–3775.
[34]
Qin J, Yuan J, Li L, Liu H, Qin R, et al. (2009) In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed Pharmacother 63: 241–248.
[35]
Li J, Lee AS (2006) Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6: 45–54.
[36]
Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225–242.
[37]
Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16: 1384–1390.
[38]
Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, et al. (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40: 124–132.
[39]
Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, et al. (2011) In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 105: 393–402.
[40]
Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, et al. (2003) Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 9: 4324–4331.
[41]
Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, et al. (2002) Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62: 356–358.
[42]
Williams CS, Watson AJ, Sheng H, Helou R, Shao J, et al. (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60: 6045–6051.
